FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders

FSD Pharma Inc. (NASDAQ: HUGE / CSE: HUGE / FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, announced today the results of its annual general and special meeting of shareholders (“ AGSM ”), held online and in virtual-only format on June 29, 2023.

There were 148 shareholders represented in person or by proxy at the AGSM holding 48 Class A multiple voting shares (“ Class A Shares ”) and 8,176,402 Class B subordinate voting shares (“ Class B Shares ”), representing 66.67% and 20.94% of the votes attached to the Class A Shares and Class B Shares, respectively, with each Class A Share entitling the holder to 276,660 votes on all matters.

The detailed results of the vote for the election of directors of the Company are set out below.

As a result, the nominees for election as directors set out above were elected as directors of the Company to serve until the close of the next annual meeting of shareholders or until their successors are elected or appointed.

In addition, at the AGSM, the shareholders also re-appointed MNP LLP as the Company’s auditor and authorized the directors to fix the auditor’s remuneration, approved the Equity Incentive Plan originally adopted by the board on May 16, 2022, and re-approved the Stock Option Plan originally adopted by the board on February 9, 2018 and last approved by the Company’s shareholders on March 15, 2018, and approved the special resolution to amend the Company’s articles of incorporation to change the name of the Company from “FSD Pharma Inc.” to such name as may be approved by the board of directors of the Company (including the changing of the Company’s stock symbol to reflect its new name) in its sole discretion, without further approval of the shareholders of the Company (the ” Name Change “).

For more information on these matters and capitalized terms used in this press release but not defined herein, please refer to the Company’s management information circular dated May 19, 2022, on SEDAR at www.sedar.com . Details of Company’s report of voting results are available under the Company’s profile SEDAR.

Name Change

In the event that the Company proceeds with a Name Change, letters of transmittal will be made available to shareholders of the Company for use in depositing their certificates representing their Class A Shares or Class B Shares to the Company’s transfer agent in exchange for new certificates representing the new name of the Company. Shareholders are not required to take any action at this time. Non-Registered Shareholders holding their Class A Shares or Class B Shares through an Intermediary should note that Intermediaries may have different procedures for processing a name change than those that will be put in place by the Company for Registered Shareholders. If you hold your Class A Shares or Class B Shares with an Intermediary and you have questions in this regard, you are encouraged to contact your intermediary. Shareholders should not destroy any share certificates and should not submit any certificates until requested to do so, if required.

You may contact the transfer agent, Marrelli Trust Company Limited by mail at c/o Marrelli Transfer Services Corp., 82 Richmond Street East, Toronto, Ontario M5C 1P1, by telephone at 416-361-0737 or over email at info@marrellitrust.ca.

FSD Pharma Inc. is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences, Inc., a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound, FSD201, a proprietary ultra-micronized PEA formulation, for the treatment of inflammatory diseases. Lucid Psychss Inc., a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-Psych and Lucid-MS. Lucid-Psych is a molecular compound identified for the potential treatment of mental health disorders, and expanding this category, the Company is investigating other products addressing acute medical needs due to the abuse of drugs such as alcohol. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders.